Combining S-1 and Gemcitabine for Pancreatic Cancer
Author Information
Author(s): Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, Kato H, Saisho H
Primary Institution: Chiba University, Chiba, Japan
Hypothesis
The study aims to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of S-1 combined with gemcitabine in patients with metastatic pancreatic cancer.
Conclusion
The combination of S-1 and gemcitabine was well tolerated and showed promising antitumor activity, warranting further phase II studies.
Supporting Evidence
- 21 patients with advanced pancreatic cancer were enrolled in the study.
- 10 out of 21 patients showed a complete or partial response to the treatment.
- The median survival time for patients was 9.3 months.
Takeaway
Doctors tested a new medicine called S-1 with an existing one called gemcitabine to see if they work better together for patients with pancreatic cancer.
Methodology
This was an open-label, single-centre, nonrandomised, dose-escalating phase I study where S-1 was given orally and gemcitabine was administered intravenously.
Limitations
The study was limited to a small sample size and was only a phase I trial focused on safety and tolerability.
Participant Demographics
{"total":21,"men":10,"women":11,"age":{"median":61,"range":"48-73"},"ecog_status":{"0":8,"1":11,"2":2},"sites_of_metastatic_disease":{"liver":18,"lung":3,"peritoneum":2}}
Statistical Information
Confidence Interval
{"median_survival_time":"9.3 months","95%_ci":"6.3-12.3"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website